title: Long-term survival effect of metoprolol in dilated cardiomyopathy. The SPIC (Italian Multicentre Cardiomyopathy Study) Group.
abstract: OBJECTIVE
  To evaluate the additive effect of metoprolol treatment on long-term incidence of fatal and non-fatal cardiac events in idiopathic dilated cardiomyopathy.
  
  
  METHODS
  586 patients with idiopathic dilated cardiomyopathy were prospectively enrolled in a multicentre registry and followed up for a mean (SD) of 52 (32) months. Metoprolol, carefully titrated to the maximum tolerated dose, was added to conventional heart failure treatment in 175 patients.
  
  
  RESULTS
  Survival and transplant-free survival at seven years were significantly higher in the 175 metoprolol treated patients than in the remaining 411 on standard treatment (81% v 60%, p < 0.001, and 69% v 49%, p < 0.001, respectively). By multivariate analysis, metoprolol independently predicted survival and transplant-free survival (relative risk reduction values for all cause mortality and combined mortality or transplantation 51% (95% confidence interval 21% to 69%), p = 0.002, and 34% (5% to 53%), p = 0.01, respectively). New York Heart Association class, left ventricular end diastolic diameter, and pulmonary wedge pressure were also predictive. Seven year survival (80% v 62%, p = 0.004) and transplant-free survival (68% v 51%, p = 0.005) were significantly higher in 127 metoprolol treated cases than in 127 controls selected from the entire control cohort and appropriately matched. Metoprolol was associated with a 30% reduction in all cause mortality (7% to 48%, p = 0.015) and a 26% reduction in mortality or transplantation (7% to 41%, p = 0.009).
  
  
  CONCLUSIONS
  The addition of metoprolol to standard heart failure treatment, including angiotensin converting enzyme inhibitors, was effective in the long-term, reducing both all cause mortality and transplantation in patients with idiopathic dilated cardiomyopathy.
authors.affiliation: Department of Cardiology, Ospedale Maggiore and University, Trieste, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Di Lenarda
authors.forename: R
authors.initials: R
authors.lastname: De Maria
authors.forename: A
authors.initials: A
authors.lastname: Gavazzi
authors.forename: D
authors.initials: D
authors.lastname: Gregori
authors.forename: M
authors.initials: M
authors.lastname: Parolini
authors.forename: G
authors.initials: G
authors.lastname: Sinagra
authors.forename: L
authors.initials: L
authors.lastname: Salvatore
authors.forename: F
authors.initials: F
authors.lastname: Longaro
authors.forename: E
authors.initials: E
authors.lastname: Bernobich
authors.forename: F
authors.initials: F
authors.lastname: Camerini
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D004070:Digitalis; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005665:Furosemide / Q000627:therapeutic use; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D015999:Multivariate Analysis; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D005665:Furosemide; D008790:Metoprolol